INDO US BIO-TECH LTD.
Financial ratio
Particulars | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|
Operational & Financial Ratios | |||
Earnings Per Share (Rs) | 5.52 | 8.07 | 4.18 |
CEPS(Rs) | 3.01 | 3.54 | 1.89 |
DPS(Rs) | 0.00 | 0.00 | 0.00 |
Book NAV/Share(Rs) | 42.01 | 35.15 | 27.05 |
Tax Rate(%) | 4.67 | -24.71 | 11.49 |
Margin Ratios | |||
Core EBITDA Margin(%) | 13.54 | 13.28 | 9.97 |
EBIT Margin(%) | 13.01 | 12.74 | 9.43 |
Pre Tax Margin(%) | 10.61 | 9.80 | 7.20 |
PAT Margin (%) | 10.11 | 12.22 | 6.37 |
Cash Profit Margin (%) | 11.01 | 12.86 | 6.91 |
Performance Ratios | |||
ROA(%) | 10.27 | 12.54 | 7.31 |
ROE(%) | 16.92 | 25.96 | 15.44 |
ROCE(%) | 15.46 | 17.65 | 15.00 |
Asset Turnover(x) | 1.01 | 1.03 | 1.15 |
Sales/Fixed Asset(x) | 12.64 | 21.23 | 28.24 |
Working Capital/Sales(x) | 1.45 | 2.00 | 2.62 |
Efficiency Ratios | |||
Fixed Capital/Sales(x) | 0.08 | 0.05 | 0.04 |
Receivable days | 164.98 | 207.85 | 192.56 |
Inventory Days | 128.46 | 95.67 | 83.98 |
Payable days | -235.19 | 0.00 | 667.11 |
Valuation Parameters | |||
PER(x) | 12.22 | 3.36 | 10.24 |
PCE(x) | 11.23 | 3.83 | 11.34 |
Price/Book(x) | 1.61 | 0.93 | 1.90 |
Yield(%) | 0.00 | 0.00 | 0.00 |
EV/Net Sales(x) | 1.49 | 0.78 | 0.99 |
EV/Core EBITDA(x) | 10.73 | 5.81 | 9.96 |
EV/EBIT(x) | 11.46 | 6.10 | 10.55 |
EV/CE(x) | 1.35 | 0.72 | 1.14 |
M Cap / Sales | 1.24 | 0.49 | 0.78 |
Growth Ratio | |||
Net Sales Growth(%) | 24.80 | 0.88 | 0.00 |
Core EBITDA Growth(%) | 29.62 | 35.18 | 0.00 |
EBIT Growth(%) | 27.47 | 36.33 | 0.00 |
PAT Growth(%) | 3.34 | 93.30 | 0.00 |
EPS Growth(%) | -31.59 | 93.30 | 0.00 |
Financial Stability Ratios | |||
Total Debt/Equity(x) | 0.33 | 0.54 | 0.52 |
Current Ratio(x) | 3.81 | 2.11 | 1.91 |
Quick Ratio(x) | 1.91 | 1.45 | 1.36 |
Interest Cover(x) | 5.42 | 4.33 | 4.24 |
Total Debt/Mcap(x) | 0.21 | 0.59 | 0.28 |